Epocal, Inc. (Epocal), a develpoer of point-of-care blood diagnostic products, has received US FDA marketing clearance for its new glucose test on the epoc Blood Analysis System. The test is intended for diagnosis and treatment of carbohydrate metabolism disorders which include diabetes mellitus and idiopathic hypoglycemia, and of pancreatic islet cell tumors. The clinical utility of the Company's point of care blood gas and electrolyte platform has been further expanded with the addition of glucose to the epoc BGEM Test Card, which includes in vitro diagnostic tests for pH, pO2, pCO2, Na, K, iCa and Hct (plus calculated values).
The FDA clearance of glucose represents one of many milestones to come for Epocal and for healthcare as we continue to expand the test menu of the first wireless and cost effective point of care testing system. said Imants Lauks, Epocal President and Founder. We are very excited to offer an award winning technology that enables hospitals worldwide to improve the delivery of patient care, reduce their operating expenses and operate more efficiently.